Clinical trials: Liver Diseases, Alcoholic
Cirrhosis Alcoholic, Fatigue Symptom
Inflammatory and Neuroimmune Guided Investigation of Underlying Fatigue in Patients With Cirrhosis
Fatigue is a common and debilitating symptom of cirrhosis, the advanced stage of chronic liver disease. Around two-thirds of people with cirrhosis experience fatigue, which can affect their ability to carry out everyday…
- Trial name
- IGNITE (NCT07899736)
- Volunteers
- 50 people
- Sponsor
- King's College London
Non-alcoholic Fatty Liver Disease
Fructose and Liver Diseases in Youth: Help Them FLY
Obesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD).
- Trial name
- FLY (NCT05528471)
- Testing
- Dietary intervention
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Severe Alcoholic Hepatitis
Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome
Alcoholic liver disease has become one of the foremost causes of chronic liver disease across the world, and a cause of considerable morbidity and mortality.
- Trial name
- NCT03827772
- Testing
- Fecal Microbiota Transplantation, Standard of care treatment
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non-alcoholic Steatohepatitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
- Trial name
- BANFF (NCT04171765)
- Testing
- BFKB8488A
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Non-Alcoholic Fatty Liver Disease, Obesity
Endoscopic Gastric Plication Using the POSE2.0 Technique for Management of Fatty Liver Disease
Primary Obesity Surgery Endoluminal 2.0, or POSE 2.0, (USGI Medical, San Clemente, CA) creates full-thickness plications of gastric tissue endoscopically to shorten the stomach and narrow its aperture for weight loss in patients…
- Trial name
- NCT05611567
- Testing
- POSE2.0 procedure, Life style and behavioral intervention
- Where
- United Arab Emirates
- Volunteers
- 42 people
- Sponsor
- Emirates Health Services (EHS)
HIV, Non-Alcoholic Fatty Liver Disease
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
Persons with human immunodeficiency virus (HIV) have higher risk of developing fatty liver disease (NAFLD) than HIV-negative persons but the reasons for this discrepancy are not known.
- Conditions
- HIV, Non-Alcoholic Fatty Liver Disease, Metabolic-Associated Steatotic Liver Disease
- Trial name
- GLAM HIV NAFLD (NCT06113003)
- Testing
- Prebiotic, Probiotic
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Vanderbilt University Medical Center
Severe Alcoholic Hepatitis, Chronic Liver Disease and Cirrhosis
Invasive Fungal Infections in Severe Alcohol-associated Hepatitis
Chronic alcohol consumption is associated with intestinal bacterial dysbiosis, yet little is known about the role of intestinal fungi, or mycobiota in liver disease.
- Trial name
- NCT04103840
- Testing
- Testing stool mycobiota
- Where
- India
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Obesity, Non-Alcoholic Fatty Liver Disease
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
- Trial name
- ATM (NCT06571474)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
Nonalcoholic Steatohepatitis
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).
- Trial name
- NCT00227110
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-Alcoholic Fatty Liver
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an…
- Trial name
- NCT03953456
- Testing
- elafibranor 120mg
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Genfit
Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome
Exercise Study in Subjects With NAFLD
Non-Alcoholic Fatty Liver Disease is the most common cause of chronic liver diseases. The benign non-alcoholic fatty liver, characterized by excessive fat accumulation, can evolve into non-alcoholic steatohepatitis and liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Exercise
- Trial name
- BestTreat (NCT03995056)
- Testing
- high-intensity aerobic interval training
- Where
- Finland
- Volunteers
- 49 people
- Sponsor
- University of Eastern Finland
Non-Alcoholic Fatty Liver Disease, Dietary Modification
Chia Supplementation and Non Alcoholic Fatty Liver Disease
Parallel to epidemic obesity, non-alcoholic fatty liver disease (NAFLD) prevalence has markedly increased during the last years, and recent data point out that one of three adults courses with this disease.
- Trial name
- NCT03942822
- Testing
- Milled chia seeds
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Non-alcoholic Fatty Liver Disease (NAFLD), Obesity
"Hepafast" in Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to investigate whether a weight reduction with "Hepafast" in combination with raw food and vegetables for two weeks followed by a meal substitution with "Hepafast" and a calorie restriction in…
- Trial name
- NCT02491229
- Testing
- Hepafast, LOGI diet
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Hohenheim
Insulin Resistance, Nonalcoholic Fatty Liver Disease
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
We hypothesize that insulin resistance is characteristic of nonalcoholic fatty liver disease as compared to age, gender, non-diabetic BMI-matched control subjects, both healthy and those with non-cirrhotic, non-steatotic liver…
- Trial name
- NCT00637520
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Duke University
MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis)
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
- Trial name
- NCT07581951
- Testing
- HSK31679
- Where
- China
- Volunteers
- 886 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non-alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steato-Hepatitis (NASH)
Metabolic Surgery for Steato-Hepatitis
Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and type 2 diabetes mellitus (T2DM) and is characterised by excess liver fat on imaging or histology. NAFLD affects up to 25% of the Western population.
- Trial name
- MeSH (NCT04282005)
- Testing
- Metabolic/Bariatric surgery, Lifestyle and Diet
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- King's College London
Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25-40%.Primary Hypothyroidism is one of Endocrinopathies who are at risk of developing NAFLD/NASH and estimated prevalence of Primary…
- Trial name
- SHIELD (NCT06373523)
- Testing
- Dapagliflozin 10mg Tab, Levothyroxine Replacement daily
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non-alcoholic Steatohepatitis
Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis
This study evaluates the dietary and therapeutic effect of supplement consisting of sublimated mare milk among patients with non-alcoholic steatohepatitis.
- Trial name
- NCT03664596
- Testing
- Sublimated mare's milk, Ursodeoxycholic Acid
- Where
- Kazakhstan
- Volunteers
- 80 people
- Sponsor
- Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese
Nonalcoholic fatty liver disease (NAFLD) is a progressive liver disease ranging from simple steatosis to cirrhosis of the liver.
- Trial name
- NCT03282305
- Volunteers
- 5,000 people
- Sponsor
- Great China Fatty Liver Consortium Limited
NASH - Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
The primary objective of the study is to compare the changes in serum ALT level among patients with non-alcoholic steatohepatitis (NASH) following 3-month treatment of 800 mg SNP-610 or the placebo.
- Trial name
- NCT03468556
- Testing
- SNP-610
- Volunteers
- 80 people
- Sponsor
- Sinew Pharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.